Institutional members access full text with Ovid®

Share this article on:

Organizing the HIV vaccine development effort

Voronin, Yegor; Snow, William

Current Opinion in HIV and AIDS: September 2013 - Volume 8 - Issue 5 - p 369–375
doi: 10.1097/COH.0b013e328363f5b6
CHANGING ENVIRONMENT IN HIV VACCINE: Edited by Nelson L. Michael and Glenda Gray

Purpose of review To describe and compare the diverse organizational structures and funding mechanisms applied to advance HIV preventive vaccine research and development and to help explain and inform evolving infrastructures and collaborative funding models.

Recent findings On the basis of models that have been tried, improved or abandoned over three decades, the field seems to have settled into a relatively stable set of diverse initiatives, each with its own organizational signature. At the same time, this set of organizations is forging cross-organizational collaborations, which promise to acquire newly emergent beneficial properties.

Summary Strong motivation to expedite HIV vaccine R&D has driven a diversity of customized and inventive organizational approaches, largely government and foundation funded. Although no one approach has proven a panacea, the field has evolved into a constellation of often overlapping organizations that complement or reinforce one another. The Global HIV Vaccine Enterprise, a responsive, rapidly evolving loose infrastructure, is an innovative collaboration to catalyze that evolution.

Global HIV Vaccine Enterprise, New York, New York, USA

Correspondence to William Snow, Global HIV Vaccine Enterprise, 64 Beaver Street, #352, New York, NY 10004, USA. E-mail:

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.